stockrow
Friday 6 November 2026
Export PACB’s income statement to Excel — free account
Pacific Biosciences of California, Inc.
PACB Healthcare Medical Devices
Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024.
- Revenue
- +5.52%
- EPS
- +7.69%
- Free cash flow
- −102.0%
- Total debt
- −0.29%
Quarter to September 2026, against a year earlier
2.27
0.16
−6.58%
Follow PACB
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.57 | 3.28 | 2.52 | 3.51 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(19.62) | (14.67) | (9.03) | (29.42) | |
P/B ratio |
0.00 | 0.00 | 170.60 | 104.86 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
7.33 | 5.83 | 4.83 | 5.79 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(8.63) | (7.87) | (6.91) | (8.33) | |
EV/FCF |
(11.90) | (11.55) | (10.86) | (7.79) | |
Quick Ratio |
3.57 | 3.90 | 4.67 | 4.32 | |
Current Ratio |
4.62 | 4.92 | 5.65 | 5.15 | |
Net Debt/EBITDA |
0.00 | (10.11) | 60.22 | (9.89) | |
Debt/Assets |
0.00% | 85.70% | 0.00% | 82.31% | |
Debt/Equity |
0.00 | (19.40) | 0.00 | 120.65 | |
Asset Turnover |
0.21 | 0.20 | 0.19 | 0.16 | |
Operating CF/Net income |
0.99 | 0.80 | 5.40 | 0.47 | |
Capex/Depreciation |
— | (0.84) | 11.12 | (0.21) | |
Interest Coverage |
(17.99) | (21.14) | (4.80) | (23.68) | |
Research and Development Expense of Revenue |
49.85% | 59.02% | 52.74% | 51.25% | |
Selling, General and Administrative Expense of Revenue |
72.52% | 85.61% | 83.79% | 76.27% | |
Intangible Assets out of Total Assets |
0.46 | 0.44 | 0.42 | 0.42 | |
Share Based Compensation of Revenue |
21.05% | 23.75% | 11.99% | 21.48% | |
Graham Net Nets |
(0.64) | (0.86) | (1.02) | (0.72) | |
Graham Number |
1.37 | 1.02 | 0.00 | 0.00 | |
Earnings Yield |
(17.72%) | (25.60%) | (32.58%) | (98.40%) | |
Free Cash Flow Yield |
(13.47%) | (15.42%) | (17.64%) | (21.20%) | |
Revenue per Share |
0.13 | 0.13 | 0.12 | 0.15 | |
Operating CF per Share |
(0.12) | (0.11) | (0.15) | (0.06) | |
Capex per Share |
0.00 | (0.01) | 0.14 | 0.00 | |
Free Cash Flow per Share |
(0.12) | (0.13) | (0.01) | (0.07) | |
Cash per Share |
0.64 | 0.76 | 0.90 | 0.93 | |
Shareholders Equity per Share |
(0.20) | (0.11) | 0.01 | 0.02 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.20) | (0.11) | 0.01 | 0.02 | |
Free Cash Flow |
(37.60) | (39.19) | (2.73) | (19.93) | |
Working Capital |
241.26 | 269.83 | 304.16 | 302.22 | |
Capital Expenditures |
— | (3.61) | 41.96 | (0.86) | |
Net Current Asset Value |
(474.62) | (446.42) | (410.48) | (403.68) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.09 | (1.13) | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
34.47 | 31.68 | 30.50 | 31.49 | |
Average Payables |
13.64 | 17.14 | 13.82 | 18.68 | |
Average Inventory |
56.72 | 57.46 | 52.51 | 54.02 | |
Average Assets |
762.13 | 788.66 | 821.58 | 1,022.27 | |
Average Common Equity |
(12.64) | 14.14 | 47.00 | 255.97 |
Columns are period end dates · fundamentals updated 5 Nov 2026